Ternary Therapeutics combines physics-informed artificial intelligence with rapid experimental validation to design molecular glue therapeutics that bring proteins together to target diseases considered previously undruggable. The company is advancing a pipeline of programs aimed at inflammatory and neuroinflammatory diseases and plans to use recently raised seed capital to scale its platform and progress programs toward preclinical development. The €4.1 million seed round was led by daphni with participation from Pace Ventures, the i&i Biotech Fund, and UKI2S (managed by Future Planet Capital). Ternary has also strengthened its leadership by appointing Dr. Ian Taylor to its board, drawing on his experience in targeted protein degradation. The company is based in London and intends to grow its team and capabilities as part of its next phase of development.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026